Pertussis
Conditions
Keywords
TDA202, acellular pertussis vaccine, antibody persistence at 2 years after vaccination, Pertagen, Boostagen, aP vaccine
Brief summary
In July 2015-November 2016, a phase II/III randomized, observer-blind,controlled study of two acellular Pertussis vaccines (aP standalone and TdaP combined vaccined) manufactured by BioNet-Asia Co., Ltd. (Bionet) and chemically-detoxified Adacel Tdap vaccine was conducted in Bangkok, Thailand in healthy subjects aged 12-17 years (Protocol No. TDA202; http://clinicaltrials.in.th; Study ID:TCTR20150703002). A total of 450 subjects were enrolled into the study at 2 study sites (Site No.1:Faculty of Medicine Siriraj Hospital; Site No.2:Vaccine Trial Centre (VTC), Faculty of Tropical Medicine, Mahidol University) with equal number of 225 subjects enrolled at each study site. During the study, the subjects had been randomized in a 1:1:1 ratio to received intramuscularly a booster dose (0.5 mL) of the study vaccines. In this current study, persistence of pertussis antibodies induced by a booster dose of recombinant acellular Pertussis based vaccines (Pertagen and Boostagen) manufactured by Bionet will be evaluated and compared to the conventional chemically-detoxified Tdap vaccine (Adacel) at 2 years after previously immunized in the TDA202 study.
Detailed description
The study population will included all subjects who participated in the TDA202 study at the Vaccine Trial Centre (VTC), Faculty of Tropical Medicine, Mahidol University, Bangkok. This is further follow-up from TDA202 clinical trial, which was completed on 29 November 2016. Target population for this study is the group of subjects who had received one dose of one of the three study vaccines in the TDA202 trial at site VTC and who had completed the study follow-up at 1-year after vaccination (223 subjects). The subjects who had received a single dose of one of the 3 study vaccines and completed 1-year follow-up visit at Day 336±28 during the TDA202 study will be called for consent process at 2 years after vaccination based on Vaccination Date in TDA202 study within ±1 month window period. Subjects aged ≥ 18 years who have signed the written informed consent form or subjects aged \< 18 years who have signed the assent form with their parent/legal guardian's given written informed consent will be screened for general health status and those who fulfill all inclusion and exclusion criteria will be enrolled into the study. Once enrolled, blood sample (approximately 5 mL) will be taken from all subjects. After blood collection, vaccination with a licensed influenza vaccine will be offered to all subjects.Blood samples will be processed for serum separation and shipped to Bionet Human Serology Laboratory where immunogenicity testing (ELISA antibodies against tetanus, diphtheria, Pertussis Toxin (PT) and Filamentous hemagglutinin (FHA) and PT neutralizing antibody by Chinese Hamster Ovary (CHO cell assay) will be performed . ELISA testing to detect antibodies against tetanus, diphtheria, and pertussis antigens (PT and FHA) will be performed for all enrolled subjects while CHO cell assay to detect PT neutralizing antibody will be performed only in the same subset of 75 subjects (25 subjects in each vaccine group) who had been selected for PT neutralizing antIbody assessment in the previous TDA202 study. Statistical analysis will be performed to evaluate antibody persistence at 2 years after one dose of each study vaccine given to subjects during the previous TDA202 study. Data management and statistical analysis will be performed by Center of Excellence for Biomedical and Public Health Informatics (BIOPHICS), Bangkok, Thailand.
Interventions
BIOLOGICALPertagen (aP BioNet)
Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202.
BIOLOGICALBoostagen (TdaP BioNet)
Boostagen (TdaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TdaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TDaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid. The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202.
BIOLOGICALAdacel
Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation. The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202
Sponsors
Mahidol University
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
1. Having participated in TDA202 study, received a single dose of one of the 3 study vaccines, and completed 1 year follow-up visit. 2. Written informed consent is obtained for subjects aged ≥18 years, or written assent and written informed consent are obtained from subjects aged \<18 years and from their parent/legal guardian, respectively, prior to study entry. 3. Capable to comply with study procedures and willing to provide with a blood sample.
Exclusion criteria
1. Received lived attenuated vaccine within 3 months prior to participating in this study. 2. Received vaccines other than lived attenuated vaccine within 28 days prior to participating in this study. 3. History of receiving blood or blood component or immunoglobulin within 3 months prior recruitment 4. History of receiving immunosuppressive drugs or systemic corticosteroid (\>0.5 mg/kg of prednisolone or equivalent for more than 14 days) within 3 months prior to recruitment. 5. Received diphtheria or tetanus or pertussis vaccine within 1 year prior to inclusion in the present study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Anti-PT GMTs (IU/mL) at 2 years after vaccination | 2 years after vaccination ± 1 month | Assessed by ELISA in all evaluable subjects by vaccine groups |
| Anti-FHA GMTs (IU/mL) at 2 years after vaccination | 2 years after vaccination ± 1 month | Assessed by ELISA in all evaluable subjects by vaccine groups |
| Anti-Tetanus GMTs (IU/mL) at 2 years after vaccination | 2 years after vaccination ± 1 month | Assessed by ELISA in all evaluable subjects by vaccine groups |
| Anti-Diphtheria GMTs (IU/mL) at 2 years after vaccination | 2 years after vaccination ± 1 month | Assessed by ELISA in all evaluable subjects by vaccine groups |
| Seroconversion rates of subjects with booster response in anti-PT antibody titers at Day 28 and 2 years after vaccination compared to baseline in all evaluable subjects by vaccine groups | 2 years after vaccination ± 1 month | Booster response: * In initially seronegative subjects (baseline titer \< 5 IU/mL), post-vaccination antibody concentrations ≥ 20 IU/mL; * In initially seropositive subjects with baseline titer ≥ 5 IU/mL and \< 20 IU/mL, an increase of at least 4 times (≥ 4-fold) the baseline titer; * In initially seropositive subjects with baseline titer ≥ 20 IU/mL, an increase of at least 2 times (≥ 2-fold) the baseline titer |
| Seroconversion rates of subjects with booster response in anti-FHA antibody titers at Day 28 and 2 years after vaccination compared to baseline in all evaluable subjects by vaccine groups | 2 years after vaccination ± 1 month | Booster response: * In initially seronegative subjects (baseline titer \< 5 IU/mL), post-vaccination antibody concentrations ≥ 20 IU/mL; * In initially seropositive subjects with baseline titer ≥ 5 IU/mL and \< 20 IU/mL, an increase of at least 4 times (≥ 4-fold) the baseline titer; * In initially seropositive subjects with baseline titer ≥ 20 IU/mL, an increase of at least 2 times (≥ 2-fold) the baseline titer |
| Seroconversion rates of subjects with > 0.1 IU/mL of anti-Tetanus at Day 28 and 2 years after vaccination compared to baseline in all evaluable subjects by vaccine groups | 2 years after vaccination ± 1 month | Assessed by ELISA |
| Seroconversion rates of subjects with > 0.1 IU/mL of anti-Diphtheria at Day 28 and 2 years after vaccination compared to baseline in all evaluable subjects by vaccine groups | 2 years after vaccination ± 1 month | Assessed by ELISA |
| PT neutralizing GMTs (IU/mL) at 2 year after vaccination | 2 years after vaccination ± 1 month | PT neutralizing antibody assessed by Chinese Hamster Ovary (CHO) in subset of each vaccine group |
| Seroconversion rate of PT neutralizing antibody increase ≥ 4-fold at 2 years after vaccination compared to baseline | 2 years after vaccination ± 1 month | PT neutralizing antibody assessed by Chinese Hamster Ovary (CHO) in subset of each vaccine group |
Countries
Thailand
Outcome results
None listed